Estrogen Sensing Through GPER1 Regulates Normal and Malignant Liver Growth
AssigneeThe Brigham and Women S Hospital, Inc.
InventorsWolfram Goessling, Saireudee Chaturantabut
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for the prevention and treatment of an abnormal tissue condition in the liver (e.g., liver cancer) of a subject, based on the administration of an inhibitor of a G protein-coupled estrogen receptor 1 (GPER1).
Claims19
A method of treating a subject having liver cancer, the method comprising administering a therapeutically effective amount of an inhibitor of G protein-coupled estrogen receptor 1 (GPER1), thereby treating the liver cancer in the subject.
A method of preventing the development of an abnormal growth condition in a liver tissue of a subject, the method comprising administering an inhibitor of GPER1 to a subject in need thereof, thereby preventing the development of the abnormal growth condition.
A method of selecting a subject for treatment with an inhibitor of GPER1, the method comprising:
- obtaining a liver tissue sample from the subject;
- performing an assay to determine whether GPER1-positive hepatocytes are present in the liver tissue sample;
- identifying a subject as having GPER1-positive hepatocytes;
- and
- selecting the identified subject for treatment with an inhibitor of GPER1.
Dependencies are inferred from the claim text.